Evidence map›Paper›PMID 41142809›Full record

ReviewFrontiers in immunology2025

Coumarins in the tumor-immune application: from molecular mechanisms to therapeutic innovations.

Yufan Zhao, Lingjie Jing, Leng Han, Cheng Guo, Quanjun Yang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yufan ZhaoDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lingjie JingDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Leng HanDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cheng GuoDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Quanjun YangDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coumarin compounds represent a class of natural or synthetic molecules characterized by a benzo-α-pyrone skeleton. Their diverse substituents and extensive biological activities have garnered significant attention in the fields of anti-tumor therapy and immune regulation in recent years. This article systematically reviews the mechanisms by which coumarins influence tumor immunity. Coumarins directly inhibit tumor progression by inducing apoptosis in tumor cells, inhibiting cellular proliferation, and blocking epithelial-mesenchymal transition (EMT) and angiogenesis. However, they reshape the tumor microenvironment (TME) by regulating platelet function, macrophage polarization, T cell activity, NK cell cytotoxicity, and cytokine networks, thereby enhancing the host's anti-tumor immune response. Despite the promising potential of coumarins in tumor immunotherapy, their mechanisms are complex, their clinical translation remains limited, and safety concerns warrant further investigation. This review summarizes the research progress on coumarins, discusses the challenges and future directions for their development, and aims to provide a comprehensive reference for the mechanism analysis and translational applications of coumarins in tumor immunotherapy. Furthermore, it seeks to facilitate the development of innovative drugs derived from natural products and to promote their clinical translation.

Indexed as

Antineoplastic AgentsCoumarinsImmunotherapyNeoplasmsAnimalsEpithelial-Mesenchymal TransitionHumansTumor MicroenvironmentAntineoplastic AgentsCoumarinscoumarinsimmunoregulationimmunotherapynatural productstumor microenvironment

Identifiers

PMID41142809
PMCPMC12546247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.